Thermo Fisher Scientific (TMO) Cash & Equivalents (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Cash & Equivalents for 18 consecutive years, with $3.3 billion the latest figure, recorded in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $3.3 billion, down 21.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 billion (down 21.29% YoY), and the FY2025 annual result was $9.9 billion, up 145.75% from the prior year.
• Cash & Equivalents was $3.3 billion for Q1 2026 at Thermo Fisher Scientific, down from $9.9 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $9.9 billion in Q4 2025 and troughed at $1.9 billion in Q3 2022.
• Average Cash & Equivalents over 5 years is $4.8 billion, with a median of $4.1 billion recorded in 2025.
• Year-over-year, Cash & Equivalents slumped 75.73% in 2022 and soared 145.75% in 2025.
• Over 5 years, Cash & Equivalents stood at $8.5 billion in 2022, then dropped by 5.24% to $8.1 billion in 2023, then sank by 50.37% to $4.0 billion in 2024, then soared by 145.75% to $9.9 billion in 2025, then plunged by 66.97% to $3.3 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $3.3 billion in Q1 2026, $9.9 billion in Q4 2025, and $2.0 billion in Q3 2025.